Objective: To estimate oral clearance of nifedipine and to determine demogr
aphic and clinical covariates that affect nifedipine clearance in a clinica
l population.
Methods: Apparent oral clearance of nifedipine and protein binding were mea
sured in 226 patients receiving sustained-release nifedipine formulations f
or hypertension and corollary artery disease (black men, n = 111; black wom
en, n = 27; white men, n = 64; white women, n = 24), Mean age +/- SD was 71
+/- 11 pears, and mean weight was 86 +/- 17 kg. Nifedipine concentrations
were analyzed by HPLC, protein binding was measured by equilibrium dialysis
, clearance and covariate effects were estimated by a nonlinear mixed effec
ts population model, and statistical analyses were performed by a nonlinear
mix-ed-effects model (clearance) and ANOVA (protein binding).
Results:Clearance was significantly slower in black subjects (8.9 +/- 0.7 m
L/min/kg; mean +/- SE) compared with white subjects (11.6 +/- 0.8 ml/min/kg
; P=.00004) and in men compared with women (9.3 +/- 0.6 versus 12.1 +/- 1.5
mL/min/kg; P=.0021). Reported alcohol use (alcohol, 8.6 +/- 1.1 versus no
alcohol, 10.8 +/- 0.6 mL/min/kg; P =.0002) and smoking status (smoker, 8.8
+/- 2.0 versus nonsmoker, 10.2 +/- 0.6 mL/min/kg; P =.0362) also affected n
ifedipine clearance. Race and sex had no effect on protein binding of nifed
ipine (P =.29 and P =.44, respectively). No effects of age, stable coronary
artery disease, or reported intake of beta-blockers on nifedipine clearanc
e were detected in this primarily elderly population with hypertension.
Conclusions: The data suggest that race, sex, and environmental factors are
identifiable sources of interindividual variation in the oral clearance of
nifedipine, a CYP3A substrate. Our experience also suggests that data from
clinical populations may be biased with regard to age, sex, and formulatio
n selection, and covariates may not be independently distributed, which can
limit analyses.